Advances about screening and preventive treatment of Mycobacterium tuberculosis latent infection in students

doi:10.19983/j.issn.2096-8493.20210141

Abstract

Abstract:

About a quarter of the whole population were infected with Mycobacterium tuberculosis worldwide, of which about 5%-10% will develop into tuberculosis patients. Students with pulmonary tuberculosis in the schools, were prone to cause cluster diseases. Implementing active screening, preventive treatment and other intervention measures in advance were significantly to reduce the secondary cases and the spread of tuberculosis in schools. This article summarized the epidemic status of latent tuberculosis infection of the students in schools, analyzed the testing results of different screening methods, and summarized the objective, treatment scheme, treatment outcome, side effect and feasibility of preventive treatment for students with latent tuberculosis infection, aiming to provide policy suggestion for the prevention and control of the latent infection of students in schools.

Key words: Students, Mycobacterium tuberculosis, Latent tuberculosis, Protective agents

YANG Kui, CHEN Wei. Advances about screening and preventive treatment of Mycobacterium tuberculosis latent infection in students[J]. Journal of Tuberculosis and Lung Disease , 2021, 2(4): 361-365. doi: 10.19983/j.issn.2096-8493.20210141

Figures/Tables 1

References 58

[1]	World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization, 2020.
[2]	中华人民共和国国家统计局. 中华人民共和国2020年国民经济和社会发展统计公报[DB/OL]. [2021-02-28]. http://www.stats.gov.cn/tjsj/zxfb/202102/t20210227_1814154.html.
[3]	陈伟, 陈秋兰, 夏愔愔, 等. 2008—2012年全国学生结核病疫情特征分析. 中国防痨杂志, 2013, 35(12):949-954.
[4]	中华人民共和国卫生部, 中华人民共和国教育部. 关于印发《学校结核病防控工作规范(试行)》的通知. 卫办疾控发〔2010〕133号. 2010-08-16.
[5]	World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018.
[6]	中华人民共和国国家卫生和计划生育委员会. WS 196—2017 结核病分类. 2017-11-09.
[7]	中华人民共和国国家卫生健康委员会. 中国结核病预防控制工作技术规范(2020年版). 国卫办疾控函〔2020〕279号, 2020-04-02.
[8]	Pahal P, Sharma S. Secondary Pulmonary Hypertension. Treasure Island: StatPearls Publishing, 2021.
[9]	辛朝雄, 陈美淑, 郑伟娇, 等. TB-PPD和BCG-PPD检测结核分枝杆菌感染的应用分析. 临床医学, 2014, 34(2):49-51.
[10]	张慧民, 戚霓虹. TB-PPD与BCG-PPD在结核病诊断中的对比. 中国继续医学教育, 2021, 13(25):169-171. doi: 10.3969/j.issn.1674-9308.2021.25.046. doi: 10.3969/j.issn.1674-9308.2021.25.046
[11]	雷娟, 刘广天, 田晓梅, 等. 2933例大学新生BCG-PPD和TB-PPD筛查试验结果分析. 宁夏医科大学学报, 2021, 43(8):854-856. doi: 10.16050/j.cnki.issn1674-6309.2021.08.018. doi: 10.16050/j.cnki.issn1674-6309.2021.08.018
[12]	许怡, 张海丛, 吕颖, 等. 结核菌素皮肤试验和γ干扰素释放试验诊断高危人群潜伏性结核感染的影响因素分析. 临床误诊误治, 2018, 31(4):67-71. doi: 10.3969/j.issn.1002-3429.2018.04.021. doi: 10.3969/j.issn.1002-3429.2018.04.021
[13]	Lamberti M, Uccello R, Monaco MGL, et al. Tuberculin skin test and Quantiferon test agreement and influencing factors in tuberculosis screening of healthcare workers: a systematic review and meta-analysis. J Occup Med Toxicol, 2015, 10:2. doi: 10.1186/s12995-015-0044-y. doi: 10.1186/s12995-015-0044-y pmid: 25670962
[14]	Pourakbari B, Mamishi S, Benvari S, et al. Comparison of the QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube interferon-γ release assays: A systematic review and meta-analysis. Adv Med Sci, 2019, 64(2):437-443. doi: 10.1016/j.advms.2019.09.001. doi: 10.1016/j.advms.2019.09.001 URL
[15]	Ruan Q, Zhang S, Ai J, et al. Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis. Clin Rheumatol, 2016, 35(2):417-425. doi: 10.1007/s10067-014-2817-6. doi: 10.1007/s10067-014-2817-6 URL
[16]	Chiappini E, Accetta G, Bonsignori F, et al. Interferon-γ release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a systematic review and meta-analysis. Int J Immunopathol Pharmacol, 2012, 25(3):557-564. doi: 10.1177/039463201202500301. doi: 10.1177/039463201202500301 pmid: 23058005
[17]	Della Bella C, Spinicci M, Alnwaisri HFM, et al. LIOFeron^®TB/LTBI: A novel and reliable test for LTBI and tuberculosis. Int J Infect Dis, 2020, 91:177-181. doi: 10.1016/j.ijid.2019.12.012. doi: 10.1016/j.ijid.2019.12.012 URL
[18]	丁晓艳, 陆伟, 刘巧, 等. γ干扰素释放试验与结核菌素皮肤试验应用于人群结核潜伏性感染诊断的比较. 江苏预防医学, 2018, 29(3):237-240,327. doi: 10.13668/j.issn.1006-9070.2018.03.001. doi: 10.13668/j.issn.1006-9070.2018.03.001
[19]	赵森林, 韩荣花, 禄春燕, 等. γ-干扰素释放试验对不同年龄段患者结核杆菌感染的诊断价值. 实用检验医师杂志, 2020, 12(2):116-117. doi: 10.3969/j.issn.1674-7151.2020.02.015. doi: 10.3969/j.issn.1674-7151.2020.02.015
[20]	Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest, 2012, 142(1):63-75. doi: 10.1378/chest.11-3157. doi: 10.1378/chest.11-3157 URL
[21]	李磊, 孙琳, 孙超 . 体外 γ-干扰素释放试验在结核病密切接触者结核病筛查中的应用价值分析. 智慧健康, 2019, 5(3):13-14. doi: 10.19335/j.cnki.2096-1219.2019.03.007. doi: 10.19335/j.cnki.2096-1219.2019.03.007
[22]	李文欣. 体外γ-干扰素释放试验在结核病密切接触者结核病筛查中的作用. 医疗装备, 2017, 30(24):67-68.
[23]	World Health Organization. Use of tuberculosis interferon-gamma release assays (IGRAs) in low-and middle-income countries: policy statement. Geneva: World Health Organization, 2011.
[24]	姜蔼玲, 林航. 结核分枝杆菌分泌蛋白及其检测技术的研究进展. 中国现代医生, 2011, 49(16):25-27. doi: 10.3969/j.issn.1673-9701.2011.16.012. doi: 10.3969/j.issn.1673-9701.2011.16.012
[25]	Scholman T, Straub M, Sotgiu G, et al. Superior Sensitivity of Ex Vivo IFN-γ Release Assays as Compared to Skin Testing in Immunocompromised Patients. Am J Transplant, 2015, 15(10):2616-2624. doi: 10.1111/ajt.13330. doi: 10.1111/ajt.13330 pmid: 26014909
[26]	许艳, 陈海丽, 刘晓茜, 等. CFP10-ESAT6融合蛋白用于结核分枝杆菌感染诊断ELISA方法的初步研究. 中国人兽共患病学报, 2015, 31(4):315-319. doi: 10.3969/cjz.j.issn.1002-2694.2015.04.005. doi: 10.3969/cjz.j.issn.1002-2694.2015.04.005
[27]	张凯, 陶立峰, 韦芬, 等. 重组结核杆菌融合蛋白(EC)的免疫特性和临床前安全性研究. 中国防痨杂志, 2020, 42(8):807-813. doi: 10.3969/j.issn.1000-6621.2020.08.006. doi: 10.3969/j.issn.1000-6621.2020.08.006
[28]	中国防痨协会, 中国防痨协会学校与儿童结核病防治专业分会, 《中国防痨杂志》编辑委员会. 重组结核杆菌融合蛋白(EC)临床应用专家共识. 中国防痨杂志, 2020, 42(8):761-768. doi: 10.3969/i.issn.1000-6621.2020.08.001. doi: 10.3969/i.issn.1000-6621.2020.08.001
[29]	夏中颖, 刘立虎. 阜新市高中学生结核菌素筛查试验结果的分析. 中国医药指南, 2021, 19(21):73-74. doi: 10.15912/j.cnki.gocm.2021.21.034. doi: 10.15912/j.cnki.gocm.2021.21.034
[30]	蔡恩昌, 张顺三. 沧州市某县初中1900名在校学生结核菌素试验筛检结果. 职业与健康, 2011, 27(17):2007-2008.
[31]	张琳, 王超. 西安市小学入学新生结核病筛查结果分析. 中国儿童保健杂志, 2016, 24(5):547-548. doi: 10.11852/zgetbjzz2016-24-05-31. doi: 10.11852/zgetbjzz2016-24-05-31
[32]	柳巍, 曾令城, 张慧, 等. 西安市大学新生结核病筛查结果分析. 中国学校卫生, 2016, 37(2):313-315. doi: 10.16835/j.cnki.1000-9817.2016.02.049. doi: 10.16835/j.cnki.1000-9817.2016.02.049
[33]	刘新宇, 杨震, 段惠娟, 等. IFN-γ释放试验和结核菌素皮肤试验在大学入学新生体检筛查结核病潜伏感染情况的比较分析. 健康体检与管理, 2021, 2(3):264-266.
[34]	徐青龙, 廉韶斌, 卢芳, 等. 山西省运城市农村寄宿制学校结核病筛查结果分析. 中国健康教育, 2016, 32(3):213-215. doi: 10.16168/j.cnki.issn.1002-9982.2016.03.006. doi: 10.16168/j.cnki.issn.1002-9982.2016.03.006
[35]	杨枢敏, 何健, 司红艳, 等. 陇西县γ-干扰素释放试验检测结核分枝杆菌潜伏感染流行现状及影响因素研究. 中国初级卫生保健, 2016, 30(7):61-63. doi: 10.3969/j.issn.1001-568X.2016.07.0023. doi: 10.3969/j.issn.1001-568X.2016.07.0023
[36]	向美琼, 吴国瑞. 2014—2016年灵宝市入学新生结核病筛查结果分析. 河南预防医学杂志, 2018, 29(6):433-434. doi: 10.13515/j.cnki.hnjpm.1006-8414.2018.06.011. doi: 10.13515/j.cnki.hnjpm.1006-8414.2018.06.011
[37]	尹诗林, 徐祖辉, 徐慧兰, 等. 湘潭农村居民结核潜伏感染现状及影响因素研究. 中国人兽共患病学报, 2020, 36(6):509-513. doi: 10.3969/j.issn.1002-2694.2020.00.071. doi: 10.3969/j.issn.1002-2694.2020.00.071
[38]	Bennet R, Jonsson J, Nejat S, et al. Long-term Prognosis of Tuberculosis Infection and Disease in Swedish Children. Pediatr Infect Dis J, 2019, 38(10):e243-e247. doi: 10.1097/INF.0000000000002361. doi: 10.1097/INF.0000000000002361 URL
[39]	Ayele HT, Mourik MS, Debray TP, et al. Isoniazid Prophylactic Therapy for the Prevention of Tuberculosis in HIV Infected Adults: A Systematic Review and Meta-Analysis of Randomized Trials. PLoS One, 2015, 10(11):e0142290. doi: 10.1371/journal.pone.0142290. doi: 10.1371/journal.pone.0142290 URL
[40]	Smieja MJ, Marchetti CA, Cook DJ, et al. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev, 2000, 1999(2):CD001363. doi: 10.1002/14651858.CD001363. doi: 10.1002/14651858.CD001363
[41]	高东旗, 靳路鹏, 李宏, 等. 我国高校潜在结核感染者进行预防性治疗效果的Meta分析. 医学动物防制, 2015, 31(1):76-78. doi: 10.7629/yxdwfz201501025. doi: 10.7629/yxdwfz201501025
[42]	卢鹏, 成君, 路希维, 等. 科学开展预防性治疗加速遏制结核病进程. 中国防痨杂志, 2020, 42(4):316-321. doi: 10.3969/j.issn.1000-6621.2020.04.004. doi: 10.3969/j.issn.1000-6621.2020.04.004
[43]	王星, 刘全红, 李海, 等. 中学生PPD反应强度与结核发病及预防性治疗标准研究. 临床肺科杂志, 2012, 17(4):665-667. doi: 10.3969/j.issn.1009-6663.2012.04.041. doi: 10.3969/j.issn.1009-6663.2012.04.041
[44]	陈淑林, 孙德全, 石俊峰, 等. 高中生PPD反应程度与结核病发病危险的队列研究. 中国防痨杂志, 2012, 34(12):799-802.
[45]	陈卉, 张慧, 成君. 《中国学校结核病防控指南》解读. 中国防痨杂志, 2021, 43(6):542-545. doi: 10.3969/j.issn.1000-6621.2021.06.004. doi: 10.3969/j.issn.1000-6621.2021.06.004
[46]	World Health Organization. WHO operational handbook on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Geneva: World Health Organization, 2020.
[47]	陈霞, 陈文山, 刘晓静, 等. 预防性服药对PPD强阳性学生机体体液免疫和肺结核发病率的影响. 实验与检验医学, 2020, 38(2):302-304. doi: 10.3969/j.issn.1674-1129.2020.02.030. doi: 10.3969/j.issn.1674-1129.2020.02.030
[48]	韩霞, 韩威, 张春. 学校结核感染者预防性治疗效果分析. 中国热带医学, 2016, 16(10):1036-1037. doi: 10.13604/j.cnki.46-1064/r.2016.10.22. doi: 10.13604/j.cnki.46-1064/r.2016.10.22
[49]	林存智, 姜文洁, 王丽君, 等. 高校学生结核菌素试验强阳性人群异烟肼预防10年效果分析. 复旦学报(医学版), 2015, 42(5):613-617. doi: 10.3969/j.issn.1672-8467.2015.05.009. doi: 10.3969/j.issn.1672-8467.2015.05.009
[50]	Menzies D, Adjobimey M, Ruslami R, et al. Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. N Engl J Med, 2018, 379(5):440-453. doi: 10.1056/NEJMoa1714283. doi: 10.1056/NEJMoa1714283 URL
[51]	刘春玲, 严晓峰. 母牛分枝杆菌菌苗在结核病中的临床应用和研究进展. 新发传染病电子杂志, 2020, 5(4):274-276. doi: 10.19871/j.cnki.xfcrbzz.2020.04.013. doi: 10.19871/j.cnki.xfcrbzz.2020.04.013
[52]	王娟. 大中学生预防性抗结核治疗效果调查分析. 临床肺科杂志, 2011, 16(2):294-295. doi: 10.3969/j.issn.1009-6663.2011.02.079. doi: 10.3969/j.issn.1009-6663.2011.02.079
[53]	The World Bank. Middle income [DB/OL].[2021-10-07]. https://data.worldbank.org/income-level/middle-income.
[54]	许晓光, 任祖英. PPD试验对结核潜伏感染和预防性服药的影响. 中国国境卫生检疫杂志, 2021, 44(3):201-202. doi: 10.16408/j.1004-9770.2021.03.013. doi: 10.16408/j.1004-9770.2021.03.013
[55]	Li Y, Zheng YH, Lu LP, et al. Acceptance of Chemo-prophylaxis for Latent Tuberculosis Infection among High School/College Student Contacts of Tuberculosis Patients in Shanghai, China. Biomed Environ Sci, 2018, 31(4):317-321. doi: 10.3967/bes2018.041. doi: 10.3967/bes2018.041
[56]	王倪, 张慧, 黄飞, 等. 在中学开展结核菌潜伏感染者预防性治疗的可行性研究. 疾病监测, 2017, 32(1):43-47. doi: 10.3784/j.issn.1003-9961.2017.01.012. doi: 10.3784/j.issn.1003-9961.2017.01.012
[57]	李阳, 周昌明, 郑亦慧, 等. 在结核病患者儿童/青少年密切接触者中开展结核病预防性治疗的可行性定性研究. 上海预防医学, 2018, 30(3):170-175. doi: 10.19428/j.cnki.sjpm.2018.18663. doi: 10.19428/j.cnki.sjpm.2018.18663
[58]	戚广浩, 马谢民, 周长山, 等. 北京市通州区大学新生预防性治疗结核病实施现状调查分析. 中国防痨杂志, 2011, 33(1):25-27.

治疗方案	治疗对象及剂量(mg/kg)	用法
6H或9H	儿童:10(范围7~15)mg/kg,最大剂量300mg/次成人:常规推荐5mg/kg,或不论体质量,均为300mg/次	1次/d
3H-Rft	儿童:异烟肼10~15mg/kg,最大剂量300mg/次;利福喷丁10mg/kg(>5岁),最大剂量450mg/次成人:常规推荐异烟肼900mg/次+利福喷丁900mg/次;或体质量<50kg,异烟肼500mg/次+利福喷丁450mg/次;体质量>50kg,异烟肼600mg/次+利福喷丁600mg/次	1次/周或 2次/周
4R	儿童:10(范围10~20)mg/kg,最大剂量450mg/次成人:常规推荐10mg/kg;或体质量<50kg,450mg/次;体质量>50kg,600mg/次	1次/d
3H-R	儿童:异烟肼10(范围7~15)mg/kg,最大剂量300mg/次;利福平10(范围10~20)mg/kg,最大剂量450mg/次成人:常规推荐异烟肼5mg/kg+利福平10mg/kg;或体质量<50kg,异烟肼300mg/次+利福平450mg/次;体质量>50kg,异烟肼300mg/次+利福平600mg/次	1次/d